Author

Mihaela Skobe

Tisch Cancer InstituteORCID 0000-0003-1583-6487Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

Amir HorowitziD· 2 shared Rubén Fernández‐RodrígueziD· 2 shared A. Cole Edwards· 1 shared A. Demetriou· 1 shared A. Narasimhan· 1 shared A. Rangel· 1 shared A. Tocheva· 1 shared A.M. FarkasiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Amir HorowitzORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyAntibodiesPeer-reviewedApr 20, 2026

A Human Recombinant Antibody Against DRP1 Serine 616 Phosphorylation Enables Detection of BRAFV600E-Associated Mitochondrial Division in Cancer

Shanon Nizard, Yiyang Chen, Madhavika N. Serasinghe…·Jerry E. Chipuk

This paper develops a human recombinant antibody (3G11) specific for DRP1-S616 phosphorylation, demonstrating its utility in detecting mitochondrial division in cancer, particularly in BRAFV600E-associated diseases.

DOI 10.3390/antib15020038

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintAug 27, 2025

Lymphangiogenesis driven by VEGF-C reshapes tumor immune landscape and enables tumor eradication by viral immunotherapy

Rubén Fernández‐Rodríguez, Sara Cuadrado‐Castano, A. Cole Edwards…·Mihaela Skobe

This study shows that VEGF-C promotes lymphangiogenesis in tumors, enhancing immune cell infiltration and enabling complete tumor eradication with viral immunotherapy.

1 citation

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 2, 2024

The HLA-E/NKG2A axis identifies a therapeutic vulnerability in BCG-unresponsive bladder cancer

Bérengère Salomé, Haocheng Yu, Daniel L Ranti…·Amir Horowitz

This study identifies the HLA-E/NKG2A axis as a therapeutic target in BCG-unresponsive bladder cancer by showing its role in immune evasion and impaired effector cell function.

5 citations

humanbulk RNA-seq

𝕏 PostBluesky